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Introduction
Schnitzler’s syndrome (SchS) is an autoinflammatory
disorder, characterized by chronic urticaria, fever, gam-
mopathy and bone pain. The etiology is unknown, but
interleukin-1 (IL-1) inhibition is very effective, like in
the cryopyrin associated periodic syndrome (CAPS), that
is caused by activating NLRP3 mutations. Previously, a
V198M mutation in NLRP3 was reported in one patient
with SchS, but this is a prevalent variation in the general
healthy population.
Objectives
To study presence and significance of NLRP3 genetic
variants in SchS.
Methods
We performed exome screening on peripheral blood-
derived DNA of three patients with SchS, and Sanger
sequencing of NLRP3 on peripheral blood-derived DNA
of 9 patients with SchS. Patients were further clinically
characterized and cytokine stimulation studies with per-
ipheral blood mononuclear cells (PBMCs) were
performed.
Results
We found NLRP3 genetic variants in two patients.
Exome screening revealed the known pathogenic CAPS-
causing NLRP3 c.1575C>G p.(P525L) mutation in one
patient. Confirmation by Sanger sequencing on periph-
eral blood only showed a small aberrant peak at the cor-
responding location. In another patient, we found a
hitherto unknown NLRP3 variant c.1303A>G p.(K435E),
of which the pathogenicity still needs to be determined.
None of the patients had clinically affected family
members. No V198M mutation in NLRP3 was detected
in our population of SchS.
The two patients with NLRP3 variants fulfilled the cri-
teria for SchS, and had the most severe clinical pheno-
type of the group. Also, both patients had IgG instead
of IgM gammopathy, and both patients had the highest
production of IL-1 and IL-6 upon stimulation of PBMCs
with LPS.
Conclusion
In seven of nine patients with SchS, no NLRP3 muta-
tions were found. Two patients with IgG-type SchS with
a severe phenotype carried a genetic variation in the
NLRP3 gene: in one, the novel variant K435E, and in
the other one a known mutation P525L that was
described in severe CAPS patients.
We hypothesize that somatic mosaicism or a less
pathogenic effect of the novel mutation may explain the




1Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen,
Netherlands. 2Internal Medicine, Radboud University Nijmegen Medical
Centre, Nijmegen, Netherlands. 3Genetics, Radboud University Nijmegen
Medical Centre, Nijmegen, Netherlands. 4Genetics, UMC Utrecht, Utrecht,
Netherlands.
Published: 8 November 2013
doi:10.1186/1546-0096-11-S1-A233
Cite this article as: De Koning et al.: PW03-007 - NLRP3 genetic variants
in Schnitzler’s syndrome. Pediatric Rheumatology 2013 11(Suppl 1):A233.
1Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen,
Netherlands
Full list of author information is available at the end of the article
De Koning et al. Pediatric Rheumatology 2013, 11(Suppl 1):A233
http://www.ped-rheum.com/content/11/S1/A233
© 2013 De Koning et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
